Real-world usage of Sulfonylureas in Type 2 Diabetes (JADE register)

In 2021, over half a billion people were living with diabetes worldwide, with 90% having type 2 diabetes (T2D). Practice guidelines recommend a patient-centred approach to individualize selection of glucose-lowering drugs (GLDs) in people with T2D. Compared with White populations, Asian patients with T2D had reduced insulin secreting capacity to overcome insulin resistance. Thus, improvement of insulin secretion via insulin secretagogues such as sulphonylureas (SUs) is a popular treatment strategy amongst Asian patients with T2D. Given that 80% of patients with diabetes live in low- and middle-income countries, metformin and SUs included in the World Health Organization Essential Medicine List will remain the mainstay of treatment.

Using data from the Joint Asia Diabetes Evaluation (JADE) register, a data driven quality improvement programme with structured assessment, this study evaluated treatment responses and tolerability/safety issues associated with SU-based therapy in a real-world setting. In Asia, SUs are a popular oral GLD class, often combined with metformin. Good glycemic control and safety profiles associated with the use of SUs, including gliclazide, support their position as a key treatment option in patients with T2D.

To know more : click here

International Diabetes Federation .

IDF Diabetes Atlas. 10th ed. Brussels, Belgium: International Diabetes Federation; 2021. Available at: https://www.diabetesatlas.org